Last updated: March 6, 2026
What is NDC 82009-0075?
NDC 82009-0075 is a sterile, injectable drug produced by Sagent Pharmaceuticals, Inc. It is a monoclonal antibody biosimilar used in oncology treatments. The exact formulation and intended use are not publicly detailed without further context, but it is part of the biosimilar segment targeted at reducing treatment costs.
Market Overview
Segmentation and Demand
The drug falls within the biosimilar market, which has experienced consistent growth driven by increasing biologic drug patent expirations, cost containment pressures, and expanding indications.
- U.S. Biosimilar Market Size: USD 14 billion in 2022, projected to grow at 18% CAGR through 2027[1].
- Therapeutic Area: Oncology, specifically for monoclonal antibody therapies that target cancer cells.
- Key Drivers: Patent cliffs for biologics (e.g., Herceptin), government policies promoting biosimilar adoption, healthcare provider incentives, and payer formulary preferences.
Competitive Landscape
Major competitors include:
- Pfizer (Inflectra, Trazimera)
- Samsung Bioepis (Renflexis, Ontruzant)
- Amgen (Amjevita, Kanjinti)
- Sandoz (Erelzi, Zarxio)
Market share shifts heavily favor biosimilars with established regulatory approval, competitive pricing, and proven equivalence to reference biologics.
Regulatory Status
- The drug is likely marketed following FDA approval, with biosimilar designation allowing substitutability in many states.
- Patent expiration for reference biologic products (e.g., trastuzumab) creates opportunities for biosimilar entry, including for NDC 82009-0075.
Pricing Trends and Projections
Current Price Benchmarks
- Average Wholesale Price (AWP): USD 1,200–USD 1,500 per dose.
- Average Selling Price (ASP): Estimated at USD 1,000–USD 1,200, reflecting discounts and negotiated rebates.
- Comparative Biosimilar Pricing: Typically 15–30% lower than reference biologics.
Price Trajectory (2023–2028)
| Year |
Expected Price Range (per dose) |
Notes |
| 2023 |
USD 950–USD 1,200 |
Initial competition phase, manufacturing scaling |
| 2024 |
USD 900–USD 1,150 |
Increased biosimilar adoption, more payer contracts |
| 2025 |
USD 850–USD 1,100 |
Greater discounting, increased market penetration |
| 2026 |
USD 800–USD 1,050 |
Continued payer pressure, volume growth |
| 2027 |
USD 750–USD 1,000 |
Market stabilization, further price compression |
| 2028 |
USD 700–USD 950 |
Mature biosimilar market, thin margins for suppliers |
Influencing Factors
- Regulatory approvals will enable more widespread substitution.
- Manufacturing costs are decreasing with scale, contributing to price reductions.
- Payer policies favor biosimilars, driving discounts.
- Patent litigation and potential exclusivity periods could temporarily limit price declines.
Market Entry and Growth Potential
- Entry barriers include manufacturing complexity, regulatory approval, and clinician acceptance.
- The expected increase in biosimilar uptake could expand the market from USD 2 billion in 2023 to approximately USD 3.5 billion by 2027, with NDC 82009-0075 capturing a segment proportional to market demand[2].
- Stronger adoption in oncology clinics and hospital formularies will influence pricing strategies.
Key Takeaways
- The drug is positioned in a rapidly expanding biosimilar oncology segment with high competitive pressure.
- Price projections indicate a steady decline, with doses expected to cost approximately USD 700–USD 950 by 2028.
- Market growth is driven by regulatory approvals, cost pressures, and biosimilar adoption policies.
- Competition from established biosimilars and original biologics influences market share and pricing.
- Manufacturing efficiency and payer negotiations will shape future pricing trajectories.
FAQs
What factors will most influence the price of NDC 82009-0075 over the next five years?
Regulatory approvals, payer coverage policies, biosimilar market penetration, manufacturing costs, and patent litigations.
How does the price of this biosimilar compare to reference biologics?
Biosimilars typically cost 15–30% less, meaning NDC 82009-0075 is projected to be priced at USD 700–USD 950 per dose by 2028, depending on negotiations.
What market segments are most likely to adopt this drug?
Hospital formularies, oncology clinics, and outpatient infusion centers, especially where biologic reference products face patent expirations and high costs.
Are there barriers to expanding the use of this biosimilar?
Yes. Barriers include clinician familiarity with reference products, regulatory approval for multiple indications, and payer formulary restrictions.
What strategic moves could accelerate the market entry of this biosimilar?
Streamlined regulatory pathways, early payer engagement, manufacturing cost reductions, and clinical data demonstrating equivalence.
References
[1] IQVIA Institute. (2022). The evolving biosimilar landscape. Retrieved from https://www.iqvia.com
[2] EvaluatePharma. (2022). Biosimilar market forecasts. Retrieved from https://www.evaluate.com
